Aviso Wealth Management Increases Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aviso Wealth Management raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 65.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 2,674 shares of the biopharmaceutical company’s stock after buying an additional 1,054 shares during the period. Regeneron Pharmaceuticals makes up about 1.0% of Aviso Wealth Management’s portfolio, making the stock its 22nd biggest holding. Aviso Wealth Management’s holdings in Regeneron Pharmaceuticals were worth $1,905,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the third quarter worth approximately $26,000. Truvestments Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $39,000. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 15 shares during the last quarter. OFI Invest Asset Management purchased a new position in Regeneron Pharmaceuticals during the 4th quarter worth $28,000. Finally, Larson Financial Group LLC boosted its holdings in Regeneron Pharmaceuticals by 127.3% in the 3rd quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 28 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on REGN shares. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price target for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. Robert W. Baird cut their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research note on Wednesday, February 5th. Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. Piper Sandler cut their target price on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. Finally, Citigroup lowered their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Price Performance

REGN opened at $634.14 on Wednesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $633.10 and a twelve month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market cap of $69.33 billion, a price-to-earnings ratio of 16.57, a PEG ratio of 2.34 and a beta of 0.27. The company has a fifty day simple moving average of $687.18 and a 200 day simple moving average of $806.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $11.86 earnings per share. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.56%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.